Benzinga · Oct 21, 2026
TD Cowen Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $18
TD Cowen analyst Stacy Ku maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and raises the price target from $17 to $18.
NASDAQ · AUPH
Aurinia Pharmaceuticals Inc.
Healthcare · Biotechnology
$16.65
Down-$0.56 (-3.25%)
Updated Nov 1, 2026, 12:21 AM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.1B
- P/E ratio
- 28.02
- Dividend yield
- 0.00%
- 52-week range
- $13.82 – $19.25
- Volume
- 960.84K
- Avg. volume
- 1.77M
Price performance · AUPH
AUPH price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
AUPH closed at $16.65 after 20 trading sessions, up 5.92% for the selected period.
- Last close
- $16.65
- Period change
- +5.92%
- Period low
- $15.69
- Period high
- $17.36
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $16.76 | $17.04 | $16.48 | $16.65 | 960.84K |
| Oct 29, 2026 | $17.44 | $17.58 | $17.10 | $17.21 | 744.72K |
| Oct 28, 2026 | $16.84 | $17.38 | $16.84 | $17.36 | 625.99K |
| Oct 27, 2026 | $16.98 | $17.27 | $16.96 | $17.25 | 494.48K |
| Oct 26, 2026 | $16.98 | $17.16 | $16.915 | $17.04 | 794.7K |
| Oct 23, 2026 | $17.27 | $17.31 | $16.81 | $16.86 | 649.24K |
| Oct 22, 2026 | $17.00 | $17.4099 | $16.835 | $17.33 | 780.51K |
| Oct 21, 2026 | $16.73 | $17.01 | $16.63 | $16.90 | 783.24K |
| Oct 20, 2026 | $16.60 | $16.825 | $16.556 | $16.74 | 593.68K |
| Oct 19, 2026 | $16.54 | $16.74 | $16.45 | $16.49 | 552.19K |
| Oct 16, 2026 | $16.81 | $16.81 | $16.35 | $16.51 | 737.55K |
| Oct 15, 2026 | $16.84 | $17.295 | $16.71 | $16.73 | 1.03M |
| Oct 14, 2026 | $16.24 | $16.82 | $16.1088 | $16.61 | 1.23M |
| Oct 13, 2026 | $16.46 | $16.58 | $16.21 | $16.36 | 1.14M |
| Oct 12, 2026 | $16.61 | $16.70 | $16.48 | $16.55 | 654.77K |
| Oct 9, 2026 | $16.16 | $16.97 | $16.12 | $16.65 | 849.43K |
| Oct 8, 2026 | $15.91 | $16.30 | $15.80 | $16.22 | 831.04K |
| Oct 7, 2026 | $15.56 | $16.16 | $15.50 | $16.01 | 682.53K |
| Oct 6, 2026 | $15.77 | $15.82 | $15.47 | $15.69 | 699.17K |
| Oct 5, 2026 | $15.76 | $15.80 | $15.60 | $15.72 | 802.89K |
Latest AUPH news
The latest Smart Investors Daily articles mentioning AUPH.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AUPH research
Overview
Company profile and research snapshot.
Company profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $15.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 21, 2026 | TD Cowen | Buy | — |
| Aug 7, 2026 | RBC Capital | Sector Perform | — |
| Dec 3, 2025 | Leerink Partners | Market Perform | — |
| Nov 7, 2025 | Jefferies | Buy | — |
| Nov 5, 2025 | RBC Capital | Sector Perform | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 22, 2026
Aurinia: Lupkynis Is A Cash Cow, But Competition And Patent Risks Cap The Upside
Aurinia Pharmaceuticals is now profitable, driven by LUPKYNIS, but faces a mature product with looming competition. Learn why AUPH stock is a hold.
Yahoo · Sep 16, 2026
Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company
On August 6, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported financial results for the three and six months ended June 30, and the numbers showed a company converting revenue growth into a much bigger jump in profit. Total revenue climbed 19% to $83.2 million for the quarter, but net income jumped 74% to $37.4 million, nearly four […]
Yahoo · Aug 28, 2026
Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) reached a major milestone on August 19, settling their U.S. patent dispute. Teva conceded that Aurinia’s patents covering its flagship oral lupus nephritis drug, LUPKYNIS, are valid, enforceable, and infringed by its proposed generic 7.9 mg voclosporin product. Teva agreed to delay generic commercialization until […]
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
